

# PROVIDER Update



Health Net®

NEWS & ANNOUNCEMENTS | JANUARY 11, 2018 | UPDATE 18-017 | 2 PAGES

## Health Net Blue & Gold Plan Coverage for WISDOM Breast Cancer Screening Clinical Trial

Health Net of California, Inc. (Health Net) Blue & Gold Plan HMO is providing coverage for members who participate in the Women Informed to Screen Depending on Measures of Risk (WISDOM) Study. The study is a preference-tolerant, five-year randomized clinical trial comparing annual breast cancer screening with a personalized screening schedule.

The study is being conducted by the Athena Breast Health Network, a group of breast cancer experts, health care providers, researchers, and patient advocates at five University of California Medical Centers (UC Davis, UC Irvine, UC Los Angeles, UC San Diego, and UC San Francisco) and the Sanford Health System in North and South Dakota, Iowa, and Minnesota.

### STUDY RATIONALE

WISDOM is testing an approach to optimize breast cancer detection for high-risk women while reducing unintended screening consequences (such as false positive biopsies) for low-risk women. The study hopes to show that personalized screening makes better use of available resources, screens women at appropriate intervals, improves compliance, and decreases patient anxiety.

The study will compare routine annual and personalized screening.

### STUDY DESIGN

Participants may be randomized to an annual or personalized screening arm of the study. Members with a strong preference for either study group can select the study arm by choosing to participate in the observational cohort.

- Annual arm: Participants will complete a breast health questionnaire and return for a screening mammogram in one year (unless at elevated risk).
- Personalized arm: Participants will complete a breast health questionnaire and provide a saliva sample for genetic testing. They will receive a screening recommendation based on the results of the questionnaire and their genetic testing.

In both groups, women at elevated risk will have the opportunity to discuss their risk via a telephone call with a breast health specialist, who may then recommend risk-reducing interventions.

### Who is eligible for the WISDOM study?

- Female Blue & Gold members ages 40 through 74 can participate in the study if they live in a region in which the Athena network currently operates and have never had a breast cancer or ductal carcinoma in situ (DCIS) diagnosis.

### THIS UPDATE APPLIES TO CALIFORNIA PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

### LINES OF BUSINESS:

- HMO
- PPO
- EPO
- Medicare Advantage (HMO)
- Medi-Cal
  - Kern
  - Los Angeles
    - Molina
  - Riverside
  - Sacramento
  - San Bernardino
  - San Diego
  - San Joaquin
  - Stanislaus
  - Tulare

### PROVIDER SERVICES

provider\_services@healthnet.com  
1-800-641-7761  
www.healthnet.com

### PROVIDER COMMUNICATIONS

provider.communications@healthnet.com  
fax 1-800-937-6086

---

### How can women join the study?

- Patients can join the study or email a study coordinator with questions on the study's website, <http://wisdomstudy.org>. Women interested in participating enter their name, contact information and location. They will receive an invitation email if eligible to participate.
- Providers can discuss the WISDOM study with patients who may be interested in participating and refer them directly to the WISDOM website.

### How will providers know if a patient is participating in the WISDOM Study?

- If a patient is participating in the WISDOM study, the patient can provide their clinicians with printed copies of all of their study documents which are available in their secure WISDOM study portal.
- If a patient is in the annual arm of the study, the available documents may include: 1) a WISDOM screening recommendation letter; 2) a risk report, if the patient has an elevated risk of developing breast cancer; and 3) a breast health specialist consultation note, if a consult was performed to discuss the patient's risk and preventative recommendations.
- If a patient is in the personalized arm of the study, the available documents may include those listed above for the annual arm and will also include color genomics genetic test results. If the patient is found to have a pathogenic mutation, the breast health specialist will contact the patient to discuss results and suggested referrals. For external clinicians, effort will be made to contact the patient's clinician to provide the genetic test results and consultation notes.

For patients enrolled in the study, providers can discuss the study's screening recommendation with the patient and promote adherence to their recommended screening interval.

### ADDITIONAL INFORMATION

Providers are encouraged to access Health Net's provider portal online at [provider.healthnet.com](http://provider.healthnet.com) for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact the WISDOM study coordinator for information about the study at [info@wisdomstudy.org](mailto:info@wisdomstudy.org) or at 1-855-729-2844, or Health Net Provider Services Center by email at [provider\\_services@healthnet.com](mailto:provider_services@healthnet.com) within 60 days, through the Health Net provider website at [provider.healthnet.com](http://provider.healthnet.com), or by telephone at 1-800-641-7761.

---

## Online News for Providers

Access informative articles today by logging in to [provider.healthnet.com](http://provider.healthnet.com). Select the rotating graphic to read or print articles of interest. Health Net posts new articles each week that cover a variety of topics, such as administrative procedure reminders, quality improvement tips, upcoming teleconferences, and health care initiatives.